WO2003086461A2 - Verwendung von substanzen zur behandlung von tumoren - Google Patents
Verwendung von substanzen zur behandlung von tumoren Download PDFInfo
- Publication number
- WO2003086461A2 WO2003086461A2 PCT/EP2003/003892 EP0303892W WO03086461A2 WO 2003086461 A2 WO2003086461 A2 WO 2003086461A2 EP 0303892 W EP0303892 W EP 0303892W WO 03086461 A2 WO03086461 A2 WO 03086461A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tumors
- proteins
- secreted
- active ingredient
- synthesized
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 132
- 239000000126 substance Substances 0.000 title claims description 27
- 239000004480 active ingredient Substances 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 21
- 238000001514 detection method Methods 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 76
- 102000004169 proteins and genes Human genes 0.000 claims description 72
- 201000011510 cancer Diseases 0.000 claims description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 37
- 230000014509 gene expression Effects 0.000 claims description 33
- 210000001519 tissue Anatomy 0.000 claims description 24
- 206010060862 Prostate cancer Diseases 0.000 claims description 21
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 19
- 239000013543 active substance Substances 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 206010027476 Metastases Diseases 0.000 claims description 11
- 230000009401 metastasis Effects 0.000 claims description 11
- 239000012190 activator Substances 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 239000002243 precursor Substances 0.000 claims description 10
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 102000001708 Protein Isoforms Human genes 0.000 claims description 5
- 108010029485 Protein Isoforms Proteins 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 238000009007 Diagnostic Kit Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 201000001514 prostate carcinoma Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 description 14
- 239000000499 gel Substances 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 230000003211 malignant effect Effects 0.000 description 9
- 230000002285 radioactive effect Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 6
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 5
- 102100038358 Prostate-specific antigen Human genes 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000003163 gonadal steroid hormone Substances 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 238000011472 radical prostatectomy Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000026045 iodination Effects 0.000 description 2
- 238000006192 iodination reaction Methods 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000000058 Anaplasia Diseases 0.000 description 1
- 108700004676 Bence Jones Proteins 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- HEVGGTGPGPKZHF-UHFFFAOYSA-N Epilaurene Natural products CC1C(=C)CCC1(C)C1=CC=C(C)C=C1 HEVGGTGPGPKZHF-UHFFFAOYSA-N 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 102000004989 Hepsin Human genes 0.000 description 1
- 108090001101 Hepsin Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 241000773293 Rappaport Species 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002912 lymphogenic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000003196 serial analysis of gene expression Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000021550 spleen neoplasm Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Definitions
- the present invention relates to the use of an active ingredient and a method for the prevention or treatment of tumors, diagnostic detection of diseases associated with these tumors, and pharmaceuticals related thereto
- compositions and kits are provided.
- Tumor is understood to mean a tumor or the locally defined increase in tissue volume.
- any localized swelling e.g. B. by edema, acute and chronic inflammation, aneurysmal enlargement, inflammatory organ swelling (e.g. as a so-called spleen tumor).
- tumor is understood to mean tissue neoplasms (growth, piastoma, neoplasia) in the form of spontaneous, differently uninhibited, autonomous and irreversible excess growth of the body's own tissue, which is usually associated with a different degree of loss of specific cell and tissue function.
- the tumors are divided into:
- malignant (malignant) tumors with cell nucleus polymorphism, cell atypia, anaplasia and infiltrating, usually rapid, destructive growth and
- Metastasis 3. semimalignant tumors with the histological characteristics of malignant tumors and locally infiltrating growth, but usually without metastasis.
- the tumors are classified based on the tissue from which they have evolved.
- epithelial tumors that have arisen from ectoderm and entoderm a) benign tumors such as B. adenoma, papilloma and polyps. b) malignant tumors such as B. Carcinoma.
- malignant tumors such as B. Carcinoma.
- Mesoderm a) benign tumors such as B. lipoma, fibroma, osteoma, fibroid, leiomyoma, rhabdomyoma, chondroma, b) malignant tumors such as B. sarcomas.
- Nephroblastomas Nephroblastomas, neuroblastomas, medulloblastomas,
- Retinoblastomas as well as embryonic rhabdomyosarcomas and teratomas.
- prostate cancer (carcinoma of the prostate) is the most common malignant tumor in men, which occurs primarily between the ages of 50 and 70. The majority are adenocarcinomas. This malignant tumor initially spreads within the prostate due to infiltrating growth, later there is an infiltration of the bladder glands and pelvic connective tissue, relatively rarely also of the rectum, bladder or urethra. The metastasis takes place lymphogenically and / or hematogenously. Depending on the degree of histological differentiation and clinical stage, therapy is usually carried out by radical prostatectomy with regional lymph node removal, in the advanced stage withdrawal of the male sex hormones. Here, too, the prognosis depends on the stage of the carcinoma. While at a very early stage after a radical Prostatectomy heals in approx. 90% of cases; in an advanced stage, a pessimistic prognosis is more likely.
- Prostate cancer must be distinguished from prostate hyperplasia in its diagnosis.
- Prostatic hyperplasia is a benign tumor. The prostate enlarges as a result of the numerical increase in the cells and glands of the stroma.
- Prostatic hyperplasia is the most common cause of bladder emptying disorders in men. Clinically, it begins between the ages of 40 and 50. The course is slow and in batches. Symptoms usually only appear after years with a gradual weakening of the urinary stream and delayed onset of micturition. The administration of phytotherapeutic agents can be considered as therapy or alleviation of the symptoms.
- tumor markers are substances and cellular changes whose qualitative or quantitative analysis can provide information about the presence, course or prognosis of (malignant) diseases. Tumor markers are divided into:
- tumor antigens include cell membrane-bound tumor antigens, receptors (e.g. hormone receptors, receptors for growth-promoting substances
- Leukemia Leukemia
- cell markers that indicate increased expression of oncogenes and a monoclonal Indicate cell growth, as well as molecular genetic cellular changes, especially
- the humoral tumor markers are divided into two groups. The first group summarizes the humoral tumor markers that are produced by the tumor itself. This includes z. B. tumor-associated antigens, certain
- Hormones e.g. gastrin, cortisol etc.
- enzymes e.g. neuron-specific enolase (NSE)
- proteins e.g. Bence-Jones protein
- Tumor markers in this group are e.g. B. alkaline phosphatase (AP), LDH, neopterin etc.
- the object of the invention is to provide new active substances and targets for diagnostic and therapeutic applications in tumor therapy.
- At least one active ingredient can be used for the prevention or treatment of tumors, in particular malignant tumors.
- This active ingredient influences the expression and / or the function of proteins synthesized and / or secreted by the tumor in eukaryotic cells, as a result of which the increase in tissue volume and / or the metastasis of the tumor is at least partially inhibited. Influencing the expression and / or function of the proteins synthesized and / or secreted by the tumor means in particular the inhibition of these proteins.
- This active ingredient can also be used for the manufacture of a medicament or a pharmaceutical composition for the prevention or treatment of tumors.
- a substance for the detection of the expression and / or the function of tumors in particular malignant tumors, of synthesized and / or secreted proteins in eukaryotic cells, for the detection of diseases associated with these tumors.
- Diseases associated with these tumors include B. the already mentioned prostate carcinomas, prostate hyperplasia (prostate hypertrophy) etc. But also all other tumor-associated diseases in which the proteins according to the invention are synthesized and / or secreted are included in the invention.
- a method for the prevention or treatment of tumors in particular malignant tumors, is claimed, wherein eukaryotic cells are treated with an active ingredient which influences the expression and / or the function of proteins synthesized and / or secreted by tumors, in particular inhibited, and thereby at least partially inhibits the increase in tissue volume and / or the metastasis of the tumors.
- a method for recognizing diseases which are associated with tumors is claimed, eukaryotic cells being brought into contact with a substance which expresses and / or functions thereof Detects tumors synthesized and / or secreted proteins.
- the proteins synthesized and / or secreted by the tumors can be the proteins listed in Table I shown below.
- the substance that is used for the detection and / or detection of tumor-associated diseases for. B. an antibody that is directed against these proteins, and in a detection method known to those skilled in the art, such as. B. ELISA (enzyme-linked immunosorbent assay) is used.
- ELISA enzyme-linked immunosorbent assay
- the specific antibody directed against the antigen to be determined is bound to a carrier substance (e.g. cellulose, polysterol), on which immune complexes form after incubation with the sample.
- a labeled antibody is added to these immune complexes.
- the immune-complex-bound enzyme-substrate complexes can be made visible or the antigen concentration in the sample can be determined by photometric determination of the immune-complex-bound marker enzymes by comparison with standards of known enzyme activity.
- Other substances that can be used for diagnostic detection are e.g. B. so-called oligonucleotides, which are suitable with the aid of the so-called polymerase chain reaction (PCR), to provide a quantitative detection of the proteins under investigation using a molecular genetic method in which certain DNA sections are selectively amplified.
- Scores hits determined using the MASCOT technique.
- MW Theo. Theoretical (calculated) molecular weight.
- the active substance or the substance is directed against the proteins themselves synthesized and / or secreted by the tumors.
- it can be the active ingredients such. B. act on antisense sequences. These are then directed directly against the synthesized and / or secreted proteins.
- the active ingredient can be genetically modified mutants. So z. B. by genetic engineering mutants in which the catalytic center is switched off (so-called deficient mutants), are constructed. Although the tumor-associated proteins are synthesized, they have no or only a reduced enzymatic activity. These deficient mutants, which were previously introduced into the tumor tissue, cannot fulfill the task assigned to them in the tumor tissue, which at least partially inhibits the increase in tissue volume and / or the metastasis of the tumor.
- the active ingredient is directed against activators, inhibitors, regulators and / or biological precursors of proteins synthesized and / or secreted by tumors.
- activators, inhibitors, regulators and / or biological precursors can e.g. B. up- and downstream members of the transduction cascade of the proteins listed in Table I, transcription factors that the Regulate the expression level of the proteins mentioned, but also so far unknown molecules, which are influenced by the active ingredient and are involved in the expression and / or function of the proteins mentioned.
- the active ingredient or substance be a polynucleotide which encodes a peptide, in particular a polypeptide, this peptide preferably influencing, in particular inhibiting, the expression and / or function of proteins synthesized and / or secreted by tumors.
- the active substance or the substance can be a peptide, preferably a polypeptide, this peptide preferably influencing, in particular inhibiting, the expression and / or function of proteins synthesized and / or secreted by tumors.
- the active substance or the substance can be a “small molecular compound”, preferably a “small molecular compound” with a molecular weight (MW) ⁇ 1,000.
- the malignant tumor is a prostate carcinoma.
- prostate cancer is the most common malignant tumor in men. Only if a prostate tumor can be detected at an early stage, e.g. B. by prostate-specific antigen-based mass screening (Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P: Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 417-24), the pure (preventive) surgical removal of the prostate can be considered (Bukkapatnam R, Pow-Sang JM: Radical prostatectomy in the management of clinically localized prostate cancer.
- cytotoxic agents Heidenreich A, von Knobloch R, Hofmann R: Current Status of cytotoxic chemotherapy in hormone refractory prostate cancer: Eur Urol 2001; 39: 121-30
- gene therapy Miyake H, Hara I, Kamidono S , Gleave ME: Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity.
- Immunotherapy Rosini Bl, Small EJ: Immunotherapy for prostate cancer.
- the active ingredient or the substance can be administered orally, intravenously, topically and / or by inhalation.
- the form of administration depends on the tumor itself and the constitution of the patient. Other forms of administration are known to the person skilled in the art.
- the invention encompasses a pharmaceutical composition which in particular inhibits an effective amount of at least one active substance which influences, in particular inhibits, the expression and / or the function of proteins synthesized and / or secreted by tumors, in particular malignant tumors, and optionally a pharmaceutical Carrier has.
- the active substance can be a polynucleotide which encodes a peptide, in particular a polypeptide, this peptide preferably influencing, in particular inhibiting, the expression and / or function of proteins synthesized and / or secreted by tumors, in particular malignant tumors.
- the active ingredient can be a peptide, preferably a polypeptide, this peptide preferably influencing, in particular inhibiting, the expression and / or function of proteins synthesized and / or secreted by tumors, in particular malignant tumors.
- the active ingredient can also be a so-called "small molecular compound", preferably a "small molecular compound” with a molecular weight (MW) ⁇ 1,000.
- MW molecular weight
- a pharmaceutical composition which contains an effective amount of at least one active ingredient
- Expression and / or function of activators, inhibitors, regulators and / or biological precursors of proteins, which are synthesized and / or secreted by tumors, in particular malignant tumors, are influenced, in particular inhibited, and optionally have a pharmaceutical carrier.
- the active ingredient can be a polynucleotide which encodes a peptide, preferably a polypeptide, this peptide preferably expressing and / or functioning of activators, inhibitors, regulators and / or biological precursors of tumors, in particular malignant tumors , synthesized and / or secreted proteins influenced, in particular inhibited.
- the active ingredient can also be a peptide, preferably a polypeptide, this peptide preferably influencing the expression and / or function of activators, inhibitors, regulators and / or biological precursors of proteins synthesized and / or secreted by tumors, in particular malignant tumors, inhibited in particular.
- Another active ingredient according to the invention can, for. B. a "small molecular compound", preferably a "small molecular compound” with a molecular weight (MW) ⁇ 1,000.
- the invention comprises a diagnostic kit, this diagnostic kit containing at least one substance for detecting the expression and / or function of tumors, in particular malignant tumors, of synthesized and / or secreted proteins, for the detection of diseases which are associated with these tumors stand.
- a corresponding disease is a prostate cancer, which is claimed in a particularly preferred embodiment.
- the pictures show:
- Fig. 1 Schematic representation of the experimental setup
- Fig. 2 Gel electrophoretic and MS analysis of benign and malignant prostate tissue and the equivalent spots.
- Fig. 3 Preparative gels with tissue-specific protein expression.
- Benign and malignant prostate tissue was obtained from patients who had previously undergone prostatectomy. Patients were identified using PSA (prostate specific antigen) screening and the tumors were confirmed with ultrasound. Each patient's consent was obtained prior to the operation. Immediately after the prostate was removed, it was transferred to a sterile box and cooled there. The samples were transferred to the pathologist, where tissue sections 0.5 to 1 cm thick were made. The sections were divided into a left and a right half, embedded in a "freezing matrix" and shock-frozen. The rest of the prostate was fixed in formalin and further processed according to standard procedures. To obtain tissue samples, thin sections were removed from both sides of the prostate and stained with hematoxilin-aeosine. The pathologist located and marked the tumor.
- PSA state specific antigen
- Tumor tissue was removed from the hematoxilin-aesin-stained strips and stored at -80 ° C. Marked benign control strips were removed from non-tumor-affected regions and subjected to an identical treatment If necessary, tumors were stored at - 80 ° C.
- Phosphorimager Fluji FLA 3000, Raytest, Straubenhard, Germany.
- the "multiple photon detection" measurements were carried out on 1600 pixel MPD imagers (BioTracers Inc., Herndon, USA) according to the manufacturer's instructions for at least 24 hours for a 24 cm x 24 cm area per measurement.
- a scan was carried out of 0.5 mm per pixel. In some cases, smaller regions have been scanned for a longer time to achieve higher sensitivity, or scanned at 0.25 mm per pixel to increase resolution.
- the MPD imagers have been adjusted to detect either 1-125 or 1-131 with each measurement.
- Protein identification was carried out using preparative 2D-PAGE gels. These gels contain up to 1 mg of protein, which were iodinated under the same chemical conditions as for radioactive iodination, but with the addition of non-radioactive iodine molecules. Silver-colored proteins with a running behavior like the radioactive proteins were automatically collected using the Genomic Solutions Flexys Robot. In some cases, the silver-stained proteins were removed from the gel where there was no radioactive signal, but where the silver gels differed between benign and malignant tissues. Gel parts were digested automatically with trypsin in a Genomic Solutions Investigator Progest, and 10% of the proteins obtained were transferred to a MALDI template using a Genomic Solutions Investigator ProMS robot applied.
- MALDI-TOF was carried out on a Bruker AutoFlex according to the manufacturer's instructions. If necessary, up to 90% of the peptide obtained by trypsin digestion was analyzed using the LC / MS / MS method. An LC-Packing Ultimate Micro HPLC was connected to a Bruker Esquire ion trap mass spectrometer, or the samples were analyzed using the same mass spectrometer using the Nanospray MS / MS method. Protein identification was carried out using the MASCOT program version 1.07 (Matrix Science, UK), using our own algorithms.
- Fig. 2 shows the results of these experiments.
- 2A represents malignant, 2 B benign and 2 C the comparative gel (2 A + 2 B).
- 2C shows the different expression of individual proteins in the different tissues.
- Table I shows the proteins determined using the example of two preparative gels (pH range 4-10).
- 3 shows the proteins determined using the example of two preparative gels (pH range 4-10).
- So z. B. for protein 11 (gamma-seminoprotein) a total of 5 isoforms, which were detected at pH 6.5 - 7.5, thus proving the existence of several isoforms of the same protein.
- protein 11 gamma-seminoprotein
- proteins see Table I. It can also be shown that the expression of certain proteins (see Table I) is partially inhibited, ie downregulated. Thus, these proteins are suitable targets for known and still to be developed active substances for the treatment of the diseases associated with them, and suitable targets for the detection of these diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002482612A CA2482612A1 (en) | 2002-04-15 | 2003-04-15 | Use of substances for treatment of tumors |
AU2003222293A AU2003222293B8 (en) | 2002-04-15 | 2003-04-15 | Use of substances for treating tumors |
JP2003583478A JP2005538044A (ja) | 2002-04-15 | 2003-04-15 | 腫瘍の治療のための物質の使用 |
EP03717300A EP1494716A2 (de) | 2002-04-15 | 2003-04-15 | Verwendung von substanzen zur behandlung von tumoren |
US10/511,205 US7759068B2 (en) | 2002-04-15 | 2003-04-15 | Use of substances for treating tumors |
KR10-2004-7016613A KR20050012731A (ko) | 2002-04-15 | 2003-04-15 | 종양 치료용 물질의 용도 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10217254.4 | 2002-04-15 | ||
DE10217254A DE10217254A1 (de) | 2002-04-15 | 2002-04-15 | Verwendung von Substanzen zur Behandlung von Tumoren |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003086461A2 true WO2003086461A2 (de) | 2003-10-23 |
WO2003086461A3 WO2003086461A3 (de) | 2004-02-05 |
Family
ID=28458908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/003892 WO2003086461A2 (de) | 2002-04-15 | 2003-04-15 | Verwendung von substanzen zur behandlung von tumoren |
Country Status (9)
Country | Link |
---|---|
US (1) | US7759068B2 (de) |
EP (1) | EP1494716A2 (de) |
JP (1) | JP2005538044A (de) |
KR (1) | KR20050012731A (de) |
CN (1) | CN1662255A (de) |
AU (1) | AU2003222293B8 (de) |
CA (1) | CA2482612A1 (de) |
DE (1) | DE10217254A1 (de) |
WO (1) | WO2003086461A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007141043A2 (en) | 2006-06-09 | 2007-12-13 | Proteosys Ag | Monoclonal anti-annexin a3 antibodies for the detection of prostate carcinoma |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5236844A (en) * | 1990-11-21 | 1993-08-17 | Institut National De La Sante Et De La Recherche Medicale | Analytical markers for malignant breast cancer |
US6034218A (en) * | 1996-03-15 | 2000-03-07 | Corixa Corporation | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer |
WO2000033861A2 (en) * | 1998-12-04 | 2000-06-15 | Pharmaproducts Uk Limited | Pharmaceutical compositions containing protein-disulfide isomerases |
WO2002020731A2 (en) * | 2000-09-08 | 2002-03-14 | Bayer Aktiengesellschaft | Regulation of human protein disulfide isomerase-like enzyme |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9604361D0 (en) * | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
US5856330A (en) | 1996-07-31 | 1999-01-05 | Hoechst Aktiengesellschaft | Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin |
JPH10150988A (ja) * | 1996-11-25 | 1998-06-09 | Hisamitsu Pharmaceut Co Inc | 抗腫瘍性アンチセンス薬物 |
CA2219867A1 (en) | 1997-10-31 | 1999-04-30 | Jiangping Wu | The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
US5962302A (en) | 1998-02-20 | 1999-10-05 | Incyte Pharmaceuticals, Inc. | Human N-acetylneuraminate lyase |
FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
US20030152565A1 (en) | 1998-12-04 | 2003-08-14 | Pharmaproducts Uk Limited | Pharmaceutical compositions containing proteins |
CN1300820A (zh) | 1999-12-21 | 2001-06-27 | 复旦大学 | 一种新的多肽-丙糖磷酸异构酶9和编码这种多肽的多核苷酸 |
CN1315580A (zh) | 2000-03-24 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人丙糖磷酸异构酶15和编码这种多肽的多核苷酸 |
CN1315581A (zh) | 2000-03-27 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人丙糖磷酸异构酶11和编码这种多肽的多核苷酸 |
CN1322839A (zh) | 2000-05-09 | 2001-11-21 | 上海博德基因开发有限公司 | 一种新的多肽——人丙糖磷酸异构酶10和编码这种多肽的多核苷酸 |
CN1323902A (zh) | 2000-05-16 | 2001-11-28 | 上海博德基因开发有限公司 | 一种新的多肽——人丙糖磷酸异构酶11和编码这种多肽的多核苷酸 |
WO2001094376A1 (en) | 2000-06-09 | 2001-12-13 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the cfl1 gene |
AU2001286405B2 (en) | 2000-07-31 | 2007-05-10 | Yale University | Innate immune system-directed vaccines |
-
2002
- 2002-04-15 DE DE10217254A patent/DE10217254A1/de not_active Ceased
-
2003
- 2003-04-15 KR KR10-2004-7016613A patent/KR20050012731A/ko not_active Application Discontinuation
- 2003-04-15 AU AU2003222293A patent/AU2003222293B8/en not_active Ceased
- 2003-04-15 CN CN038139111A patent/CN1662255A/zh active Pending
- 2003-04-15 WO PCT/EP2003/003892 patent/WO2003086461A2/de active Application Filing
- 2003-04-15 EP EP03717300A patent/EP1494716A2/de not_active Withdrawn
- 2003-04-15 JP JP2003583478A patent/JP2005538044A/ja active Pending
- 2003-04-15 CA CA002482612A patent/CA2482612A1/en not_active Abandoned
- 2003-04-15 US US10/511,205 patent/US7759068B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5236844A (en) * | 1990-11-21 | 1993-08-17 | Institut National De La Sante Et De La Recherche Medicale | Analytical markers for malignant breast cancer |
US6034218A (en) * | 1996-03-15 | 2000-03-07 | Corixa Corporation | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer |
WO2000033861A2 (en) * | 1998-12-04 | 2000-06-15 | Pharmaproducts Uk Limited | Pharmaceutical compositions containing protein-disulfide isomerases |
WO2002020731A2 (en) * | 2000-09-08 | 2002-03-14 | Bayer Aktiengesellschaft | Regulation of human protein disulfide isomerase-like enzyme |
Non-Patent Citations (2)
Title |
---|
LINDQUIST JONATHAN A ET AL: "ER-60, a chaperone with thiol-dependent reductase activity involved in MHC class I assembly" EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, Bd. 17, Nr. 8, 15. April 1998 (1998-04-15), Seiten 2186-2195, XP002246985 ISSN: 0261-4189 * |
See also references of EP1494716A2 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007141043A2 (en) | 2006-06-09 | 2007-12-13 | Proteosys Ag | Monoclonal anti-annexin a3 antibodies for the detection of prostate carcinoma |
Also Published As
Publication number | Publication date |
---|---|
CN1662255A (zh) | 2005-08-31 |
AU2003222293B2 (en) | 2008-07-17 |
JP2005538044A (ja) | 2005-12-15 |
US20050130876A1 (en) | 2005-06-16 |
CA2482612A1 (en) | 2003-10-23 |
KR20050012731A (ko) | 2005-02-02 |
US7759068B2 (en) | 2010-07-20 |
EP1494716A2 (de) | 2005-01-12 |
AU2003222293B8 (en) | 2008-08-07 |
WO2003086461A3 (de) | 2004-02-05 |
DE10217254A1 (de) | 2003-10-23 |
AU2003222293A1 (en) | 2003-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1720611B1 (de) | Diagnostische marker für krebs | |
DE602004008889T2 (de) | Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs | |
CN108449995B (zh) | 代表性诊断 | |
DE60029092T2 (de) | Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen | |
EP1532444B1 (de) | Verfahren zum untersuchen von körperflüssikeiten auf krebszellen sowie entsprechende analysekits | |
DE102005052384B4 (de) | Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens | |
DE69735020T2 (de) | Verfahren zur Diagnose von Prostatakrebs | |
DE60219809T2 (de) | Verbindungen und Verfahren zur Nachweiss von Karzinomen und deren Vorstufen | |
DE60023683T2 (de) | Verfahren zur unterscheidung von prostatakrebs und gutartiger prostatahyperplasie | |
Douglas et al. | Effect of exogenous testosterone replacement on prostate‐specific antigen and prostate‐specific membrane antigen levels in hypogonadal men | |
US6706483B1 (en) | Method of identifying and treating invasive carcinomas | |
AT501348A1 (de) | Verfahren zur tumordiagnose | |
Gutierrez et al. | Insulin-like growth factor-I (IGF-I) production by bovine granulosa cells in vitro and peripheral IGF-I measurement in cattle serum: an evaluation of IGF-binding protein extraction protocols | |
Wolvekamp et al. | Cautionary note on the use of end-labelling DNA fragments for detection of apoptosis | |
SHANKS et al. | Localization of erythropoietin gene expression in proximal renal tubular cells detected by digoxigenin‐labelled oligonucleotide probes | |
WO2003086461A2 (de) | Verwendung von substanzen zur behandlung von tumoren | |
US20140161813A1 (en) | Methods for the diagnosis, treatment and monitoring of cancer | |
Klencki et al. | Correlation between PCNA expression and AgNOR dots in pituitary adenomas | |
DE102004038076A1 (de) | Diagnostische Marker für Krebs | |
DE102007048636B4 (de) | Marker zur Diagnose von Krebs | |
EP1949106B1 (de) | Verfahren unter Verwendung einer Detektionseinheit, insbesondere eines Biosensors | |
AT412026B (de) | Verfahren zur diagnose eines zystischen ovarialkarzinoms | |
WO2007068478A1 (de) | Rna-helikase als marker für seltene tumore | |
WO2011135091A1 (de) | Thyroidhormonrezeptorexpression zur diagnose und prognose von brustkrebs und eierstockkrebs | |
EP1544617A2 (de) | Verwendung von an Nifie 14 bindenden Substanzen zur Diagnose und Behandlung von Krebs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003222293 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2482612 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047016613 Country of ref document: KR Ref document number: 2003583478 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003717300 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038139111 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003717300 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047016613 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10511205 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2003222293 Country of ref document: AU Date of ref document: 20030415 Kind code of ref document: B |